https://commexadvisors.com/blog Perspectives on commercial execution, pipeline discipline, and revenue predictability for life science tools and diagnostics leaders. en-us Mon, 08 Jun 2026 00:00:00 GMT CommEx Advisors RSS Generator https://commexadvisors.com/blog/the-predictability-gap https://commexadvisors.com/blog/the-predictability-gap Wed, 01 Jul 2026 00:00:00 GMT The Commercial Signal Issue 01 of The Commercial Signal — our monthly brief for science-led companies. Why great science still misses the number, what a slipping quarter really costs, and the nine-pillar system that closes the gap. https://commexadvisors.com/blog/the-power-of-1-percent https://commexadvisors.com/blog/the-power-of-1-percent Mon, 01 Jun 2026 00:00:00 GMT Commercial Strategy Greatness is rarely one decisive leap—it's a thousand 1% improvements, held in place by discipline and allowed to compound. See how single-point gains in forecast accuracy, NRR, win rate, and attach rate stack into durable commercial advantage. https://commexadvisors.com/blog/commercial-operating-system-overview https://commexadvisors.com/blog/commercial-operating-system-overview Sun, 01 Mar 2026 00:00:00 GMT Commercial Strategy Innovation is not the limiting factor—commercial execution is. The COS framework aligns strategy, sales execution, operating cadence, and performance management into a disciplined, scalable commercial engine that drives 10–15% forecast accuracy improvement and 2–3× growth impact. https://commexadvisors.com/blog/forecast-accuracy-framework https://commexadvisors.com/blog/forecast-accuracy-framework Sun, 01 Mar 2026 00:00:00 GMT Sales Execution Forecast accuracy is a direct reflection of credibility. If yours is below 60%, the issue is systemic—rooted in qualification discipline, pipeline hygiene, and operating rhythm. Here's how to fix it. https://commexadvisors.com/blog/nih-funding-commercial-strategy https://commexadvisors.com/blog/nih-funding-commercial-strategy Sun, 01 Mar 2026 00:00:00 GMT Market Insights With proposed NIH budget reductions, life science tools companies need to rethink their go-to-market strategies. Here's how to protect pipeline and revenue when your customers' funding is at risk. https://commexadvisors.com/blog/founder-led-sales-to-scalable-engine https://commexadvisors.com/blog/founder-led-sales-to-scalable-engine Thu, 15 Jan 2026 00:00:00 GMT Growth Strategy The transition from founder-led selling to a repeatable commercial model is where most growth-stage companies stall. Here's the playbook for getting it right. https://commexadvisors.com/blog/meddicc-life-science-tools https://commexadvisors.com/blog/meddicc-life-science-tools Sun, 01 Mar 2026 00:00:00 GMT Frameworks Most Life Science Tools companies don’t have a pipeline problem—they have a qualification problem. MEDDICC shifts selling from intuition to evidence-based execution, improving forecast accuracy, win rates, and pipeline quality. https://commexadvisors.com/blog/pipeline-coverage-myth https://commexadvisors.com/blog/pipeline-coverage-myth Sat, 01 Nov 2025 00:00:00 GMT Pipeline Strategy Pipeline coverage ratios are meaningless without quality. Learn how to build pipeline that converts by combining ICP discipline with rigorous stage definitions. https://commexadvisors.com/blog/vc-pe-commercial-due-diligence https://commexadvisors.com/blog/vc-pe-commercial-due-diligence Wed, 01 Oct 2025 00:00:00 GMT VC/PE Advisory Most due diligence misses the commercial execution layer. Here are the five questions that reveal whether a portfolio company can actually scale revenue.